Cell-bound complement activation products (CB-CAPs) have high sensitivity and specificity in pediatric-onset systemic lupus erythematosus and correlate with disease activity.

Autor: Hui-Yuen, J. S.1,2, Gartshteyn, Y.3, Ma, M.1,2, O’Malley, T.4, Conklin, J.4, Eichenfield, A. H.5, Imundo, L. F.3, Dervieux, T.4, Askanase, A. D.3 ada20@cumc.columbia.edu
Zdroj: Lupus. Dec2018, Vol. 27 Issue 14, p2262-2268. 7p. 3 Charts, 1 Graph.
Databáze: Academic Search Ultimate
Nepřihlášeným uživatelům se plný text nezobrazuje